Pharmacoeconomic ARB out in the market soon

High blood pressure is one of the most common medical conditions in the world today, but its treatment continues to be one of physicians’ greatest challenges.

Doctors and hypertensive patients welcome antihypertensive drugs which are effective, well-tolerated by the patients and are affordable.

Studies are now focused on the newer class of antihypertensive drugs such as the angiotensin receptor blockers (ARB).

One of these studies is the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) which showed that Losartan prevented more cardiovascular illnesses and deaths than atenolol, another antihypertensive drug.

Losartan reduced the overall risk cardiovascular illness by 13 percent, cardiovascular death by 11 percent, and fatal or non-fatal stroke by 25 percent.

A pharmacoeconomic 50 mg Losartan was launched last year in order to make hypertension treatment more affordable. However, some patients who are suffering from more severe stages of hypertension need a higher dose of Losartan.

As an answer to the clamor for more affordable antihypertensive drugs, Therapharma, a division of United Laboratories, will soon launch a 100 mg preparation of Losartan.

This is part of Unilab’s pharmacoeconomics program which aims to make medicines more affordable. The introduction of Losartan 100 mg in the market is seen to benefit the millions of Filipinos who are hypertensive.

Living up to the company tagline "Gamot na umuubra sa presyong di sobra," Unilab continues to strengthen its dedication to provide Filipinos with effective and pharmacoeconomic medicines which are reasonably priced.